Safety and Efficacy of HFA-134a Beclomethasone Dipropionate Extra-Fine Aerosol over Six Months

Louis-Philippe Boulet; André Cartier; Pierre Ernst; Pierre Larivée; Michel Laviolette

doi:10.1155/2004/823084

Canadian Respiratory Journal (Jan 2004)

Safety and Efficacy of HFA-134a Beclomethasone Dipropionate Extra-Fine Aerosol over Six Months

Louis-Philippe Boulet,
André Cartier,
Pierre Ernst,
Pierre Larivée,
Michel Laviolette

Affiliations

Louis-Philippe Boulet: Institut universitaire de cardiologie et de pneumologie, l’Université Laval, Hôpital Laval, Sainte-Foy, Quebec, Canada
André Cartier: Service de pneumologie, Hôpital du Sacré-Coeur, Montreal, Quebec, Canada
Pierre Ernst: Hôpital Général de Montréal, Montreal, Quebec, Canada
Pierre Larivée: Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Quebec, Canada
Michel Laviolette: Institut universitaire de cardiologie et de pneumologie, l’Université Laval, Hôpital Laval, Sainte-Foy, Quebec, Canada

DOI: https://doi.org/10.1155/2004/823084
Journal volume & issue: Vol. 11, no. 2
pp. 123 – 130

Abstract

Read online

OBJECTIVE: To compare the systemic safety and efficacy of hydrofluoroalkane beclomethasone dipropionate (HFA-BDP) extra-fine aerosol 800 µg/day with chlorofluorocarbon (CFC)-BDP 1500 µg/day.

Published in Canadian Respiratory Journal

ISSN: 1198-2241 (Print); 1916-7245 (Online)
Publisher: Hindawi Limited
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the respiratory system
Website: https://www.hindawi.com/journals/crj/

About the journal